MDGL241220C125000
- 0.00
- 0.000.00%
Madrigal Pharmaceuticals Newsroom
Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024?
Oppenheimer Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $400
Trump Media Saw the Largest Increase in Short Interest in October
Cantor Fitzgerald Reiterates Neutral on Madrigal Pharmaceuticals
TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390
Watching Madrigal Pharmaceuticals; Traders Circulate Unconfirmed Rumor From M&A Blog That The Co May Be Seeing Takeover Interest
Paulson & Co. Exits AngloGold Ashanti, Boosts Madrigal Pharma Among Q3 Moves
Express News | Rtw Investments, LP Reports 9.2% Passive Stake in Madrigal Pharmaceuticals Inc as of Sept 30, 2024- SEC Filing
Sagimet Draws Buy at UBS on MASH Opportunity
Here's Why Madrigal (MDGL) Is a Great Momentum Stock to Buy
Shareholders Have Faith in Loss-making Madrigal Pharmaceuticals (NASDAQ:MDGL) as Stock Climbs 55% in Past Week, Taking Three-year Gain to 267%
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
Madrigal Pharmaceuticals Insider Sold Shares Worth $1,504,703, According to a Recent SEC Filing
Madrigal Pharmaceuticals Is Maintained at Neutral by B. Riley Securities
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Travere Therapeutics (TVTX) and Regeneron (REGN)
Express News | Madrigal Pharmaceuticals Inc : B. Riley Raises Target Price to $236 From $194
Jefferies Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $400
Jefferies Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
Echosens Führt Seine Liver Health Management (LHM)-Plattform Weltweit Ein Und Rationalisiert Die Leberversorgung
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?